Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Tirzepatide is the primary driver of weight loss
A 2023 randomised study of 214 adults found only 0.9 lbs additional loss after three months compared to placebo not statistically significant
These included: Expressive communication Personal and domestic daily living skills Interpersonal skills Play-leisure skills Coping social skills Other clinical improvements observed with B12 included improvements in: Sleep Gastrointestinal symptoms Hyperactivity Tantrums Nonverbal intellectual quotient Vision Eye contact Echolalia Stereotypy Anemia Nocturnal enuresis (bed wetting) Adverse events with B12 identified by meta-analysis included: Hyperactivity (11.9%) Irritability (3.4%) Trouble sleeping (7.6%) Aggression (1.8%) Worsening behaviors (7.7%) But adverse effects were generally few, mild, not serious, and not significantly different compared to placebo
Elevate your life with access to state-of-the-art beauty and wellness treatments tailored to your needs
